Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data

@article{Cubitt2011PredictionOH,
  title={Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data},
  author={Helen E. Cubitt and J. Brian Houston and Aleksandra Galetin},
  journal={Drug Metabolism and Disposition},
  year={2011},
  volume={39},
  pages={864 - 873}
}
The current study assesses hepatic and intestinal glucuronidation, sulfation, and cytochrome P450 (P450) metabolism of raloxifene, quercetin, salbutamol, and troglitazone using different in vitro systems. The fraction metabolized by conjugation and P450 metabolism was estimated in liver and intestine, and the importance of multiple metabolic pathways on accuracy of clearance prediction was assessed. In vitro intrinsic sulfation clearance (CLint, SULT) was determined in human intestinal and… 

Tables from this paper

Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data

Combining the simplified intestinal availability model and in vitro conjugation assay make it possible to predict human FaFg regardless of UGT isoform, suggests results suggest.

Hepatic Scaling Factors for In Vitro–In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis

Scaling factors from cancerous and matched histologically normal livers are presented, for the first time, and the necessity of population-specific scaling for model-informed precision dosing in oncology is demonstrated.

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

Progress made in establishing in vitro-in vivo correlation, predicting human clearance and avoiding costly clinical failures when non-CYP-mediated metabolic pathways are predominant are highlighted.

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance

The work emphasized the importance of regional differences (cortex versus whole kidney–specific MPPGK, tissue weight, and blood flow) and a need to account for these to improve assessment of renal metabolic clearance and its extrapolation to in vivo.

Why we need proper PBPK models to examine intestine and liver oral drug absorption.

PBPK models for the intestine are described as well as semi- or whole bodyphysiological- based pharmacokinetic models to describe the impact of the flow pattern, and the intestinal transporters and enzymes and their attendant heterogeneities on intestinal and oral bioavailability.

The role of drug metabolizing enzymes in clearance

  • L. Di
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2014
While high-confidence prediction for P450-mediated clearance has been achieved, the accuracy of human clearance prediction is significantly lower for other enzyme classes, and more accurate predictive methods and models are being developed to address these challenges.

Prediction of In Vivo Hepatic Clearance and Half-Life of Drug Candidates in Human Using Chimeric Mice with Humanized Liver

In vitro and in vivo experiments with PXB mice should be useful at least for semiquantitative prediction of the PK characteristics of candidate drugs in humans, although it may not be possible to predict absolute values due to rather large prediction errors.

Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery

It is clear that the gut was the dominating organ in first-pass extraction of raloxifene in vivo in pigs and the quantification in this study support earlier human data and emphasize that intestinal glucuronidation should be considered early in the pharmaceutical development.

Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

Of all the preclinical species investigated, monkey intrinsic hydrolysis clearance obtained in hepatocytes (CLint,hepatocytes) were the most comparable to human hepatocyte data, highlighting the application of this in vitro system for investigation of prodrugs.
...

References

SHOWING 1-10 OF 85 REFERENCES

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

Intestinal glucuronidation should be incorporated into clearance prediction, especially for compounds metabolised by intestine specific UGTs, as well as in vivo clearance prediction.

Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

The metabolic ability of hepatic and intestinal pooled microsomes was compared for eight CYP3A substrates and paclitaxel, tolbutamide, S-mephenytoin, and bufuralol as CYP2C8, CYP 2C9, CYC2C19, and CYP1D6 probes, and a general agreement in the type of kinetics was observed between the two systems for the substrates investigated.

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

The applicability of combined cofactor conditions in the assessment of clearance for compounds with a differential contribution of P450 and UGT enzymes to their elimination is indicated, in particular for UGT2B7 substrates.

Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.

The hypothesis that intestinal glucuronidation modulates the amount of raloxifene undergoing bioactivation by liver is supported and corroborate the importance of assessing other competitive metabolic pathways and species differences in metabolism prior to extrapolation of bioactivation results from rats to humans.

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

The FG predictions were most successful when Papp data from Caco-2 and Madin-Darby canine kidney cells transfected with human MDCK-MDR1 cells were used directly; in contrast, the use of physicochemical parameters resulted in significant FG underpredictions.

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

The results demonstrate that the upper small intestine serves as the major site for intestinal CYP3A-mediated first-pass metabolism and provides a rationale for interindividual differences in oral bioavailability for some CYP 3A substrates.

Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro.

Tetrahydrothiophenium ion formation rate per milligram of cytosolic protein was constant along the length (assessed in 30-cm segments) of three individual small intestines and busulfan conjugation in vitro was comparable permilligram in liver and intestinal cytosol.

Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Investigation of raloxifene glucuronidation by human liver and intestinal microsomes and identified the responsible UDP-glucuronosyltransferases (UGTs) found UGT1A1 and 1A8 were found to catalyze the formation of both the 6-beta- and 4'-beta- glucuronides, whereas UGT2A10 formed only the 4'- beta-glUCuronide.

Predictions of the In Vivo Clearance of Drugs from Rate of Loss Using Human Liver Microsomes for Phase I and Phase II Biotransformations

For highly bound drugs (>95% plasma protein bound), the addition of a plasma protein binding term increased the accuracy of the prediction of in vivo clearance, suggesting the substrate loss method may be used to accurately predict hepatic clearance of drugs.
...